We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Funds Comparison Study of Prograf vs. Generic Counterparts
FDA Funds Comparison Study of Prograf vs. Generic Counterparts
October 23, 2012
The FDA has given $2.7 million to University of Cincinnati researchers to study whether generic versions of the transplant drug Prograf have the same efficacy as Astellas Pharma’s branded product.